Gendelman HE. Neural immunity: friend or foe? J Neurovirol. 2002;8(6):474–9.
Article CAS PubMed Google Scholar
Amor S, Puentes F, Baker D, van der Valk P. Inflammation in neurodegenerative diseases. Immunology. 2010;129(2):154–69.
Article CAS PubMed PubMed Central Google Scholar
Lauer AN, Tenenbaum T, Schroten H, Schwerk C. The diverse cellular responses of the choroid plexus during infection of the central nervous system. Am J Physiol Cell Physiol. 2018;314(2):C152–65.
Weiss LM, Dubey JP. Toxoplasmosis: A history of clinical observations. Int J Parasitol. 2009;39(8):895–901.
Article PubMed PubMed Central Google Scholar
Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol. 2000;30(12–13):1217–58.
Article CAS PubMed PubMed Central Google Scholar
Montoya JG, Liesenfeld O. Toxoplasmosis Lancet. 2004;363(9425):1965–76.
Article CAS PubMed Google Scholar
Ehret T, Torelli F, Klotz C, Pedersen AB, Seeber F. Translational rodent models for research on parasitic protozoa-a review of confounders and possibilities. Front Cell Infect Microbiol. 2017;7:238.
Article PubMed PubMed Central Google Scholar
Fischer HG, Nitzgen B, Reichmann G, Hadding U. Cytokine responses induced by Toxoplasma gondii in astrocytes and microglial cells. Eur J Immunol. 1997;27(6):1539–48.
Article CAS PubMed Google Scholar
Blanchard N, Dunay IR, Schluter D. Persistence of Toxoplasma gondii in the central nervous system: a fine-tuned balance between the parasite, the brain and the immune system. Parasite Immunol. 2015;37(3):150–8.
Article CAS PubMed Google Scholar
Wohlfert EA, Blader IJ, Wilson EH. Brains and Brawn: Toxoplasma Infections of the Central Nervous System and Skeletal Muscle. Trends Parasitol. 2017;33(7):519–31.
Article PubMed PubMed Central Google Scholar
Biswas A, Bruder D, Wolf SA, Jeron A, Mack M, Heimesaat MM, et al. Ly6C(high) monocytes control cerebral toxoplasmosis. J Immunol. 2015;194(7):3223–35.
Article CAS PubMed Google Scholar
Biswas A, French T, Dusedau HP, Mueller N, Riek-Burchardt M, Dudeck A, et al. Behavior of neutrophil granulocytes during Toxoplasma gondii infection in the central nervous system. Front Cell Infect Microbiol. 2017;7:259.
Article PubMed PubMed Central Google Scholar
Steffen J, Ehrentraut S, Bank U, Biswas A, Figueiredo CA, Holsken O, et al. Type 1 innate lymphoid cells regulate the onset of Toxoplasma gondii-induced neuroinflammation. Cell Rep. 2022;38:8.
Parlog A, Harsan LA, Zagrebelsky M, Weller M, von Elverfeldt D, Mawrin C, et al. Chronic murine toxoplasmosis is defined by subtle changes in neuronal connectivity. Dis Model Mech. 2014;7(4):459–69.
PubMed PubMed Central Google Scholar
Lang D, Schott BH, van Ham M, Morton L, Kulikovskaja L, Herrera-Molina R, et al. Chronic Toxoplasma infection is associated with distinct alterations in the synaptic protein composition. J Neuroinflammation. 2018;15(1):216.
Article PubMed PubMed Central Google Scholar
French T, Dusedau HP, Steffen J, Biswas A, Ahmed N, Hartmann S, et al. Neuronal impairment following chronic Toxoplasma gondii infection is aggravated by intestinal nematode challenge in an IFN-gamma-dependent manner. J Neuroinflammation. 2019;16(1):159.
Article PubMed PubMed Central Google Scholar
Flegr J. Effects of toxoplasma on human behavior. Schizophr Bull. 2007;33(3):757–60.
Article PubMed PubMed Central Google Scholar
Kannan G, Pletnikov MV. Toxoplasma gondii and cognitive deficits in schizophrenia: an animal model perspective. Schizophr Bull. 2012;38(6):1155–61.
Article PubMed PubMed Central Google Scholar
Xiao J, Buka SL, Cannon TD, Suzuki Y, Viscidi RP, Torrey EF, et al. Serological pattern consistent with infection with type I Toxoplasma gondii in mothers and risk of psychosis among adult offspring. Microbes Infect. 2009;11(13):1011–8.
Article CAS PubMed Google Scholar
Castano Barrios L, Da Silva Pinheiro AP, Gibaldi D, Silva AA, Machado Rodrigues ESP, Roffe E, et al. Behavioral alterations in long-term Toxoplasma gondii infection of C57BL/6 mice are associated with neuroinflammation and disruption of the blood brain barrier. PLoS ONE. 2021;16(10): e0258199.
Article CAS PubMed PubMed Central Google Scholar
Berrett AN, Gale SD, Erickson LD, Brown BL, Hedges DW. Toxoplasma Gondii moderates the association between multiple folate-cycle factors and cognitive function in U.S. Adults. Nutrients. 2017;9(6):34.
Arling TA, Yolken RH, Lapidus M, Langenberg P, Dickerson FB, Zimmerman SA, et al. Toxoplasma gondii antibody titers and history of suicide attempts in patients with recurrent mood disorders. J Nerv Ment Dis. 2009;197(12):905–8.
Zhu S. Psychosis may be associated with toxoplasmosis. Med Hypotheses. 2009;73(5):799–801.
Torrey EF, Bartko JJ, Yolken RH. Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophr Bull. 2012;38(3):642–7.
Article PubMed PubMed Central Google Scholar
Dunay IR, Gajurel K, Dhakal R, Liesenfeld O, Montoya JG. Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice. Clin Microbiol Rev. 2018;31(4):8.
Abad C, Gomariz RP, Waschek JA. Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP. Curr Top Med Chem. 2006;6(2):151–63.
Article CAS PubMed Google Scholar
Toth D, Szabo E, Tamas A, Juhasz T, Horvath G, Fabian E, et al. Protective effects of PACAP in peripheral organs. Front Endocrinol (Lausanne). 2020;11:377.
Hirabayashi T, Nakamachi T, Shioda S. Discovery of PACAP and its receptors in the brain. J Headache Pain. 2018;19(1):28.
Article PubMed PubMed Central Google Scholar
Waschek JA. VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair. Br J Pharmacol. 2013;169(3):512–23.
Article CAS PubMed PubMed Central Google Scholar
Szabo E, Patko E, Vaczy A, Molitor D, Csutak A, Toth G, et al. Retinoprotective effects of PACAP eye drops in microbead-induced glaucoma model in rats. Int J Mol Sci. 2021;22(16):8.
Karlsson M, Zhang C, Mear L, Zhong W, Digre A, Katona B, et al. A single-cell type transcriptomics map of human tissues. Sci Adv. 2021;7(31):3.
The Human Protein Atlas database. www.proteinatlas.org/ENSG00000141433-ADCYAP1/single+cell+type. Accessed 21 Mar 2022.
Soles-Tarres I, Cabezas-Llobet N, Vaudry D, Xifro X. Protective effects of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide against cognitive decline in neurodegenerative diseases. Front Cell Neurosci. 2020;14:221.
Article CAS PubMed PubMed Central Google Scholar
Langer I. Mechanisms involved in VPAC receptors activation and regulation: lessons from pharmacological and mutagenesis studies. Front Endocrinol (Lausanne). 2012;3:129.
Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev. 2009;61(3):283–357.
Article CAS PubMed Google Scholar
Pozo D, Delgado M, Martinez C, Gomariz RP, Guerrero JM, Calvo JR. Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal macrophages. Biochim Biophys Acta. 1997;1359(3):250–62.
Article CAS PubMed Google Scholar
Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev. 2004;56(2):249–90.
Article CAS PubMed Google Scholar
Delgado M, Pozo D, Martinez C, Garrido E, Leceta J, Calvo JR, et al. Characterization of gene expression of VIP and VIP1-receptor in rat peritoneal lymphocytes and macrophages. Regul Pept. 1996;62(2–3):161–6.
Article CAS PubMed Google Scholar
Figueiredo CA, Dusedau HP, Steffen J, Gupta N, Dunay MP, Toth GK, et al. Immunomodulatory effects of the neuropeptide pituitary adenylate cyclase-activating polypeptide in acute toxoplasmosis. Front Cell Infect Microbiol. 2019;9:154.
留言 (0)